DSM SABIC ACQUIRES DSM's POLYOLEFINS
DSM is active worldwide in life
science products, performance materials, polymers and industrial
chemicals. The group has annual sales of EUR 8 billion and
employs about 22,000 people (year-end 2001) at more than 200
DSM ranks among the global leaders in many of its fields. The company's strategy is aimed at generating sales of approx. EUR 10 billion in 2005. At least 80% of these sales should be generated by specialties, i.e. advanced chemical and biotechnological products for the life science industry and performance materials.
As such, this strategy represents a continuation of the company's ongoing transformation and concentration on global leadership positions in high-added-value activities characterized by high growth and more stable profit levels.
DSM is a highly integrated group of companies that is active worldwide in the field of chemicals, life science products and plastics with:
$5.9 billion in sales
More than 200 sites around the globe
DSM's headquarters are in Heerlen, The Netherlands. DSM's activities are organized in business groups corresponding to three coherent product/market combinations:
Life Science Products
Polymers & Industrial Chemicals
The company's principal products are:
intermediates and ingredients for the pharmaceutical and food industries
performance materials (like engineering plastics, resins and synthetic rubbers) for the automotive and electrical/electronics industries
polymers as well as industrial chemicals for a wide range of manufacturing industries
DSM is the global market leader for several products including:
enzyme technologies and products
... operates two steam crackers which mainly produce polymer raw materials. The most important of these are ethylene and propylene, which are supplied to other DSM business groups as feedstocks for the production of polyethylene, polypropylene, EPDM rubber and acrylonitrile.
The product range further includes butadiene, benzene, MTBE, gasoline components, raw materials for hydrocarbon resins, aromatics, carbon black oil and styrene.
At the core of the DSM Hydrocarbons division, is its pair of naptha steam crackers with a combined annual capacity of over one million tons of ethylene and approximately 470 thousand tons of propylene. Additionally, DSM Hydrocarbons operates several modern downstream plants for benzene, butadiene, gasolines and an integrated unit for MTBE, carbon-black feedstocks, solvents and C9 resinfeed.
ranks among the leading producers of polyethylenes in Europe in terms of both market position and cost price.
DSM Polyethylenes produces a variety of polyethylenes using several technologies. These materials are mainly used in the packaging industry.
...manufactures polypropylene as well as a wide range of compounds based on this polymer.
The business group has a total production capacity of 750,000 tpa (including DSM Polyolefine). The products are used in packaging (flexible and rigid), fibres, automotive parts (e.g. bumper systems), pipes and electrical and electronic (E&E) components and equipment.
The business group aims to expand its position as a leading polypropylene supplier. In Western Europe, DSM holds a market share of 11% in polypropylene.
In 1997, DSM established DSM Polyolefine in Gelsenkirchen and took over the polyethylene and polypropylene activities of Veba Oel. This represented the ideal platform for implementing the group’s polymer strategy.
DSM currently has a polypropylene capacity of 750,000 tpa divided over three plants (total capacity of 550,000 tpa) at the large, integrated DSM site at Geleen (The Netherlands) and one plant in Gelsenkirchen in Germany (DSM Polyolefine GmbH, the former Vestolen GmbH). By the year 2001, when a new plant in Gelsenkirchen comes on stream, capacity will amount to more than 1 million tpa.
Existing facilities with an annual capacity of approximately 300,000 metric tons of polyolefines are being modernized and expanded, and two modern new plants will boost production to almost a million metric tons per year by the year 2001 to triple present production with a workforce of 500.
DSM Hydrocarbons Americas, Inc.
is a sales office whose primary business focus is on the sales and procurement of products for DSM Hydrocarbons in The Netherlands.
DSM Hydrocarbons Americas’ geographical focus is the USA, Canada, Mexico, Venezuela and Colombia. For the Latin American market DSM Hydrocarbons Americas also sells caprolactam, cyclohexanone and specialty chemicals.
Contract to sell Roche’s vitamins, carotenoids and fine chemicals
business to DSM signed
DSM and Roche announced today that the contract to acquire Roche’s vitamins, carotenoids and fine chemicals business has been signed. This transaction is subject to approval by the anti-trust authorities.
For Roche, this agreement allows to further focus our group on our two high-tech pillars, pharmaceuticals and diagnostics to further establish our position as a leading, innovation driven healthcare company.”
2003/2/21 Financial Times
DSM pays EUR 300 M less for Roche vitamins division.
DSM is to pay EUR 300 M less for Roche's vitamins division because the slowdown in economic growth has had an adverse effect on the vitamins market.
May 1, 2003 Dow Jones
EU Delays Decision On DSM's Purchase Of Roche Operations
ロシュ・ビタミン・ジャパン株式会社は、新社名「DSM ニュートリションジャパン 株式会社」で、日本市場におけるさらなるビジネス展開を推進
オランダのスペシャリティ・ケミカル・カンパニーであるDSM N.V. (本社：オランダ ヘーレン市、会長：ピーター・エルバディング、以下 DSM）は、DSMによるロシュ社（スイス）のビタミンおよびファインケミカル事業の買収にともなう、日本における事業統合を正式に完了したことを、本日発表しました。
これにより、ロシュ・ビタミン・ジャパン株式会社（本社：東京都大田区、代表取締役社長：レオ・ダーム）は、2004年1月1日付けで「DSM ニュートリションジャパン株式会社」（DSM Nutrition Japan K.K. 以下 DSMニュートリション ジャパン）に社名変更し、DSMの日本市場におけるライフサイエンス事業の中核を担う組織として、引き続き高品質な製品の開発と製造に努めてまいります。
Royal DSM N.V. intends to participate in North China Pharmaceutical Group Corporation
Today, Royal DSM N.V.,
headquartered in Heerlen, The Netherlands, confirmed that it is
engaged in discussions with North China Pharmaceutical Group
Corporation (“NCPC”) of Shijiazhuang石家庄,
Hebei Province河北省, People’s Republic of China, regarding a
strategic partnership via a.o. participation in the equity ownership
of North China Pharmaceutical Company, Ltd. (“NCPC Ltd.”), a company which is listed on
the Shanghai stock exchange. DSM’s equity participation in NCPC
Ltd. is related to the establishment of joint ventures in the
area of vitamins and anti-biotic products.
NCPC, together with its affiliates, is one of the largest vitamins and antibiotics manufacturers in the People’s Republic of China, originally established in 1953 in Hebei Province. NCPC comprises 28 controlled subsidiaries, 12 associated companies, and an additional 20 indirectly controlled subsidiaries. Total 2003 group revenues of NCPC are approximately RMB 7 billion (EUR 700 million).
DSM Nanjing to start expanded CPL plant, full rates end '05
DSM Nanjing Chemical Co is looking to start up its newly-expanded caprolactam plant in Nanjing, China in the first half of September, a company source said Friday.
The plant with its capacity now doubled to 140,000 mt/yr is currently in a pre-commissioning state, and on water runs to get the functions going, the source added. Operations will be stabilized initially at 70% of capacity, with the full start-up by the end of 2005.
China Chemical Reporter 2005/9/7
DSM Deretil Formed JV
with Shangyu Yuntao Chemicals
global leader in the field of development, production and sales
of side chains for betalactamic antibiotics and the Chinese
company Shangyu Yuntao Chemicals Company, announced that they have formed
a Joint Venture for the production of DL Phenyl Glycine and D(-) Phenyl
Deretil acquired 51% of the shares and obtained an option to
acquire the remaining 49% to gain full ownership of the
company within the next three years.
“With this joint venture we realize the opportunity to combine Deretil’s superior technology with the low cost infrastructure of a Chinese manufacturer. This enables us to further build on the value proposals we can make to our customers and supply them with the quality they need in the highly competitive anti-infective market”, concludes Lluis Franquesa, General Manager of DSM Deretil at the closing of the agreement.
DSM Deretil is part of DSM N.V. through its DSM Anti-Infectives Business Group. And Shangyu Yuntao Chemicals Company is a privately owned company located in Shangyu 上虞 of Zhejiang province浙江省 in eastern China, and was established in 2001. Shangyu Yuntao Chemicals produces DL Phenyl Glycine and D(-) Phenyl Glycine, has annual sales of around US$7.3 million.
DSM Deretil is a business unit of DSM Anti-Infectives, one of the business groups of DSM. DSM is active worldwide in life science and nutritional products, performance materials and industrial chemicals.
We are a leading company in the field of the development, production and sales of side chains for betalactamic antibiotics. DSM Deretil has a worldwide presence, long experience in the market and a strong customer focus orientation.
Globalization is a must for the pharmaceutical industry and DSM Deretil is in the lead. For crucial subjects like research & development, information & communication technology , personnel training, production sites, production processes, international customers and logistics this is firmly addressed in DSM Deretil's management strategy.
DSM Anti-Infectives comprises DSM’s activities in the field of development, production and sale of raw materials, intermediates, and bulk actives for anti-infectives such as antibiotics (for combatting bacterial infections) and anti fungals (for combatting fungal infections).
R&D Center in China
world-leading supplier of life science and nutritional products,
performance materials and industrial chemicals, today opened its
first Research & Development (R&D) Center in China. The
center is located in Shanghai.
The DSM R&D Center China will be the company's main R&D base in the country and will form a vital part of DSM's global R&D network. In addition to carrying out product and applications development work, the center will support DSM's businesses in several other ways: by tracking market trends, by proactively responding to the needs of customers, and through interaction with the external know-how infrastructure, such as partners in universities, scientific research institutes and industry. DSM Nutritional Products, DSM Food Specialties and DSM NeoResins will be the first three DSM businesses to operate facilities at this R&D Center.
DSM Nutritional Products, formerly Roche Vitamins and Fine Chemicals, is the world's leading supplier of vitamins and carotenoids to the feed, food, pharmaceutical and cosmetic industries.
DSM Food Specialties is a leading producer of specialty food and feed ingredients. The product portfolio includes enzymes, yeast extracts, natamycin, starter cultures and media, cheese and meat coatings, antibiotic residue tests and natural beta-carotene.
DSM NeoResins We offer waterborne technologies such as acrylic emulsions and polyurethane dispersions for application in water-based coatings and water-based printing inks.
DSM sells styrene-butadiene rubber business to Lion Chemical Capital LLC
DSM and Lion
Chemical Capital LLC today announce the agreement on
the sale of the DSM business unit SBR
(styrene-butadiene rubber) to Lion Chemical Capital LLC. The
transaction will take the form of an asset deal.
The sale is a result of DSM’s corporate strategy, Vision 2005: Focus & Value, which has transformed the company into a specialty company focusing on life science products and performance materials over the last few years. As a consequence, the SBR business no longer fits into DSM's portfolio.
Lion Chemical Capital
In 2004, Lion acquired the largest independent rubber compounding business in North America from PolyOne Corporation. The business, Excel Polymers, has over USD 400 million in revenues and includes eight plants located in the US, Mexico, U.K. and China. Excel Polymers provides effective solutions to both high volume and the most challenging technical rubber applications. The businesses will be operated as independent operations.
Lion closes on DSM rubber business
Lion Chemical Capital, LLC, a private New York-based investment firm, has announced the closing sale on DSM Copolymer Styrene-Butadiene Rubber (SBR). The new company will be called Lion Copolymer, LLC and will continue to be headquartered in Baton Rouge, La. Terms of the transaction were not disclosed.
SBR is used primarily by tire manufacturers and makers of conveyor belts, hoses and gaskets.
With this sale, Lion Copolymers will be one of the largest SBR producers in the United States, with revenues exceeding $200 million.
Chinese resins producer Syntech
Dutch specialty chemicals company Royal DSM N.V. today acquired Syntech, a producer and marketer of coating resins. Syntech has annual sales of around USD 30 million, generated with a broad portfolio of coating resins. The acquisition of Syntech further strengthens DSM's liquid coating resins portfolio and will enable DSM to further accelerate the expansion of its activities in the Chinese market.
Syntech's activities are concentrated at one location in Shunde (Guangdong province 広東省順徳). The site includes production facilities, self-owned R&D laboratories and a pilot plant for product development.
DSM to double capacity for engineering plastics in China 江陰市
Royal DSM N.V.
today announces the opening of its new
compounding site for engineering plastics at Jiangyin
in the Jiangsu province of China on April 26, 2006. This
project will double the total capacity for the product lines
Stanyl(R) PA46, Akulon(R) PA6 and Arnite(R) PBT. These materials
are used in manufacturing key molded components for the
automotive, electrical and electronics, consumer and industrial
DSM to build two
new engineering plastic plants at Chemelot site, Geleen (NL)
Royal DSM N.V. today announces that it has decided to construct two new manufacturing facilities at its Chemelot site in Geleen, the Netherlands. DSM is making these investments in response to excellent market growth for two of the company’s top specialty products, Stanyl(R) polyamide 46 and Stamylan(R) UH ultra-high molecular weight polyethylene, which is used among other things as a raw material for Dyneema(R) high strength fibers. The new Stanyl(R) plant and the new Stamylan(R) facility, which will each double existing production capacity, are scheduled to come on line in 2008. The total investment will be around EUR 100 million.
Stanyl, the highest performance polyamide in the world, is a unique, high-crystallinity material that exhibits exceptional heat resistance, stiffness and strength, chemical resistance and processability. In addition, it has a low coefficient of friction and resists creep and deformation. Automotive applications of Stanyl include chain tensioners, engine covers, gears, sensors and clutch rings. Electrical applications include connectors, circuit breaker housings, microswitches, electric motor parts, and a variety of components for consumer electronics. Consumer applications include muffler covers for gas operated tools, water kettle components including safety switches, and a variety of other hand and power tool components.
Stamylan UH is a very high molecular weight polyethylene that exhibits excellent toughness and resistance to abrasion, outstanding chemical resistance and good low friction, non-stick characteristics. It is widely used for wear-resistant components in industrial, bulk materials handling and sports equipment as well as in ultra-strong fibers.
Dyneema is a super strong polyethylene fiber that offers maximum strength combined with minimum weight. It is up to 15 times stronger than quality steel and up to 40% stronger than aramid fibers, both on a weight-for-weight basis. Dyneema is an important component in marine and offshore ropes, in cables and nets, in safety gloves for the metalworking industry and in fine yarns for applications in sporting goods and the medical sector. In addition, Dyneema is used in bullet resistant armor and clothing for police and military personnel.
DSM Engineering Plastics
DSM Engineering Plastics is a business group forming part of DSM’s Performance Materials cluster. DSM Engineering Plastics is a global supplier of Stanyl PA 46 and Akulon 6 and 66 polyamides, Arnitel TPE-E, Arnite PBT and PET polyesters, Xantar polycarbonate, Yparex extrudable adhesive resins, and Stamylan UH Ultra High Molecular Weight PE. These materials are used in technical components for electrical appliances, electronic equipment and cars, in barrier packaging films as well as in many mechanical and extrusion applications. The business group had annual sales of EUR 705 million in 2005. It employs 1400 people worldwide and has eight production locations in Europe, the USA and Asia. With StanylR, it is the global market leader in high heat polyamides.
2007/9/14 DSM 工場
DSM starts initiative to extend its material portfolio for the orthopedic industry
Royal DSM N.V. today announces the start of an initiative to enter the market of ultra high molecular weight polyethylene (UHMWPE) for use in total joint arthroplasty 関節形成 and other medical devices. In the coming years DSM Biomedical will make significant investments in a research and development program focused on UHMWPE grades with optimized material properties, specifically aimed at currently unmet clinical needs in this orthopedic 整形外科 segment. This strategic material development links on to DSM’s activities in the Biomedical Emerging Business Area, which is an important element of DSM’s strategy Vision 2010 - Building on Strengths.
DSM is already active in the orthopedic market with Dyneema Purity®, a fiber technology which was developed specially to obtain the required highest levels of quality and purity in medical applications, such as orthopedic implants.
Although DSM currently already is one of the major suppliers of Ultra High Molecular Weight Polyethylene, supplied under the trade name Stamylan® UH, DSM’s UHMWPE is not applied in arthroplasty applications yet.
Dyneema fibers are made using a DSM patented (1979) method called gel spinning.
A precisely heated gel of UHMWPE is processed by an extruder through a spinneret
Dyneema Purity® is a highly purified grade of Dyneema® developed specifically for use in medical applications where maximum strength and minimum weight are required. It is ideal for orthopedic implants, for example, as it allows smaller implants to be used, and is flexible and resistant to abrasion. Similarly, its strength can be used for surgical instruments for minimally invasive procedures.
Typical applications for Stamylan UH (supplied in the form of a powder)
- Automotive industry: battery separators
- Electrical: cable clamps, contact breakers and insulation components
- Food and beverage industry: star wheels, sliding rails, scrolls and feed worms, guide and deflector rollers, chute tables
- Pulp and paper industry: suction box covers, scraper blades, foil covers
- Textile industry: pickers and buffers
- Chemical industry: pumps, valves and seals
- Leisure industry: sliding surfaces for skis and snowboards
- General machinery: bearings, gears, rollers, chain guides and tensioners
- Bulk materials handling mining and agriculture: linings for silos, hoppers, trucks and ships, industrial drains
- Porous parts: dust collection filters, water purification, perfume absorption, sound reduction and fluidisation
- Ultra strong PE fibers: cables, ropes, fishing lines, ballistic vests, lightweight composite armour for vehicles and helmets
- Microporous film: Lithium-ion battery separators, micro-filtration, specialty fabrics and tape
DSM to invest in caprolactam plant at Chemelot, Geleen, the Netherlands
Royal DSM N.V. has decided to invest in capacity expansion and modernization of the caprolactam plant at the Chemelot Industrial Park in Geleen (NL). The total investment costs amount to EUR 25 million. This investment will allow DSM to gradually expand the capacity of the plant according to market demands.
Caprolactam is the key raw material for Nylon-6, a highly versatile material that is used to make not only textile, carpet and technical fibres, but also engineering plastics and packaging films. Nylon-6 is found in numerous applications ranging from conveyor belts, parachutes and lingerie to automotive air-inlets and packaging for fresh food products.
DSM says its Fibre Intermediates subsidiary is the leading global supplier of caprolactam, the key raw material for nylon 6.
It has three operating companies with a combined annual capacity of more than 0·5 million tons in Europe, the Americas and Asia Pacific.
DSM Fiber Intermediates increased its production capacity by expanding the annual caprolactum capacity at the DSM Nanjing Chemical Corporation from 70,000 tons per year to 140,000 tons by the end of 2005.
2007/10/8 DSM 高強度ポリエチレン
DSM expands Dyneema® production in Greenville, USA 高強度ポリエチレン
Royal DSM N.V. today announces that it will invest to expand Dyneema® UD (UniDirectional bullet resistant sheet) production by 25% in its Greenville, North Carolina (USA) manufacturing facility.
The investment is driven by the increasing demand for Dyneema® UD in the US market for personal and especially vehicle security and protection against terrorism. Production in Greenville has a strong focus on supplying the US army and law enforcement agencies. By adding extra capacity to its highly integrated Greenville site, DSM remains capable of meeting increasing demand for its products and highly committed to the long term development of the US market. The new line is expected to come on stream in mid 2008. This news also comes on the heels of the recent decision to invest in a new Technical Service center at DSM’s Stanley, NC (USA) facility.
“Investing in further growth of Dyneema® in the US is in line with the focus on our local, and faithful customers and fits perfectly with the recently announced acceleration of DSM’s strategy, Vision 2010 - Building on Strengths, in which market-driven growth and innovation is one of the key pillars,” comments Nico Gerardu, member of DSM’s Managing Board and responsible for the Performance Materials cluster. “DSM will continue to further expand its global capacity for Dyneema® fiber and UD materials to maintain its global market leadership position. To our customers this should provide another example of our commitment to be the world’s most reliable and capable quality supplier of HPPE products.”
About DSM Dyneema
DSM Dyneema is the inventor and manufacturer of Dyneema®, the world’s strongest fiber™. Dyneema® is an ultra strong polyethylene fiber that offers maximum strength combined with minimum weight. It is up to 15 times stronger than quality steel and up to 40% stronger than aramid fibers, both on weight for weight basis. Dyneema® floats on water and is extremely durable and resistant to moisture, UV light and chemicals. The applications are therefore more or less unlimited. Dyneema® is an important component in ropes, cables and nets in the fishing, shipping and offshore industries. Dyneema® is also used in safety gloves for the metalworking industry and in fine yarns for applications in sporting goods and the medical sector. In addition, Dyneema® is also used in bullet resistant armor and clothing for police and military personnel.
Dyneema® is produced in Heerlen (The Netherlands) and in Greenville, North Carolina (U.S.A.). DSM Dyneema is also a partner in a high modulus polyethylene (HMPE) manufacturing joint venture in Japan. Further information on DSM Dyneema is available at www.dyneema.com.
DSM to increase engineering plastics compounding capacity in China by 50%
Royal DSM N.V. today announces that it will expand its engineering plastics compounding capacity at the site in Jiangyin 江陰(China). The investment will increase the capacity of the compounding plant by 50% and the added capacity will be operational towards the end of 2008. This comes as an enhancement to DSM’s existing capacity, which was doubled in 2006 with the opening of this new greenfield site.
DSM opened its greenfield compounding plant for engineering plastics in Jiangyin in 2006 and is currently building a world-scale polyamide 6 polymerization plant at the same site, which will start production in 2008. At the Jiangyin site DSM manufactures Stanyl®, a high performance polyamide (PA46), Akulon® PA6, Arnite® PBT and PET, and Arnitel® TPE, which it supplies to customers throughout Asia in the automotive, electrical/electronics and manufacturing industries. The Jiangyin site also houses a Research and Development Center for engineering plastics, from which DSM supports customer developments throughout the region.
DSM invests in ‘green’ polymers from CO2
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has made an investment in Novomer Inc. The companies also plan to sign a cooperation agreement. Financial details of the investment will not be disclosed.
Novomer is developing a technology platform to use carbon dioxide and other renewable materials to produce performance polymers, plastics and other chemicals. The company’s products combine environmental benefits with improved materials performance and can be used in a range of applications, from injection molded parts for electronics to paper coatings and medical implants.
DSM to sell Special Products to Arsenal Capital as first divestment following accelerated Vision 2010
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, has reached an agreement in principle with Arsenal Capital Partners (United States) on the sale of DSM Special Products BV. It is the first divestment following the accelerated Vision 2010 strategy. The transaction is expected to close in early Q2 2008, subject to regulatory and legal approvals.
The sale is a result of the acceleration of DSM’s transformation into a Life Sciences and Materials Sciences company. As outlined in the strategic program Vision 2010 - Building on Strengths a number of businesses which do not fit in the strategy, including DSM Special Products, will be divested.
DSM Special Products is
the producer of Purox, an ingredient used in food as well as in a
range of industrial applications. It also produces an ingredient
for VevoVitall®, a product for the animal health
market that will remain with DSM Nutritional Products. The supply
of this ingredient for VevoVitall® to DSM Nutritional Products will
not be affected due to an existing long-term supply agreement.
DSM Special Products employs 126 people in Rotterdam and Sittard
(Netherlands). They will all transfer to the new owner.
Benzoic Acid 安息香酸(Purox B), Sodium Benzoate (Purox S)
DSM invests in development of bio-based materials in China
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a USD 20 million financing round in Tianjin Green Bio-Science Co., Ltd (China). The proceeds will be used to build China’s largest manufacturing plant for Polyhydroxyalkanoates (PHA) in the Tianjin Economic Development Area (TEDA).
微生物産生ポリエステル（ポリヒドロキシアルカン酸 PHA) は、バイオマス由来の有機物をある種の微生物に与えることにより得られる脂肪族ポリエステル
The plant’s construction will commence in Q2 2008, and is expected to start production in early 2009. It will have an annual production capacity of 10,000 tons of PHA.
About Tianjin Green
Bio-Science Co., Ltd.
Tianjin Green Biosciences Co., Ltd (TGBS), located in the High-Tech Park of Tianjin University in TEDA, Tianjin, is dedicated to developing and producing biodegradable polymers and products. Research demonstrates that the PHAs TGBS developed have excellent biodegradable, processing performance and biocompatibility. Due to its special properties, the PHA could be developed for use of high value added products including high strength fiber, pressure sensitive adhesive, aqueous adhesive, human tissue engineering product, etc., as well as applications in food and commodity packaging, with the potential to substitute 50% petroleum-based plastic in application.
DSM inaugurates Akulon® PA6 polymer plant in China
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces the inauguration of its new polymer plant in Jiangyin (Jiangsu province, China) 江蘇省江陰市. The plant produces high viscosity grades of Akulon® polyamide 6 (PA6) aimed at the fast growing high end food packaging market in Asia. Construction of the plant, which was announced in September 2006, involved several tens of millions of USD.
DSM Engineering Plastics
DSM Engineering Plastics is a Business Group in the Performance Materials cluster of DSM, with sales in 2007 of EUR 839 million and approximately 1,550 employees worldwide. It is one of the world's leading suppliers of engineering thermoplastics offering a broad portfolio of high performance products including Stanyl® high performance polyamide and Akulon® 6 and 66 polyamides, Arnitel® TPE-E, Arnite® PBT and PET polyesters, Xantar® polycarbonate, Yparex® extrudable adhesive resins. These materials are used in technical components for electrical appliances, electronic equipment and cars, in barrier packaging films as well as in many mechanical and extrusion applications. With Stanyl®, it is the global market leader in high heat polyamides.
DSM and NCPC sign
contracts to establish nutrition and anti-infectives joint
ventures in China
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, North China Pharmaceutical Group Corporation Ltd. (NCPC GroupCo) of Shijiazhuang, Hebei Province, People’s Republic of China, NCPC ListCo, the listed affiliate of NCPC and the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) of Hebei Province today announce that they have signed the contracts regarding investment by DSM in NCPC GroupCo and the establishment of three joint ventures in the areas of nutritional products and anti-infectives.
These contracts are the follow-up to the announcements made at the end of 2004 and the further detailing of the agreement in late 2005. DSM will make a strategic investment in NCPC by obtaining a minority share (9.77%) in NCPC GroupCo. Parties will establish one nutrition production joint venture (Vitamin C) and two anti-infectives抗感染薬 business joint ventures (anti-infectives active pharmaceutical ingredients and intermediates). In the two anti-infectives joint ventures DSM will have a 51% interest. In the Nutrition production joint venture, DSM will hold a minority share of 30%.
The total cash investment by DSM following completion, will amount to approximately USD 110 million. In addition, DSM will with this investment leverage its technology and management capabilities.
North China Pharmaceutical Group Corporation (NCPC) is one of the largest vitamin and antibiotics manufacturers in People’s Republic of China. NCPC is originally started in 1953 in the Hebei Province and now has eight production technology platforms including microbian pharmaceutical, chemical synthesis pharmaceutical, biochemical pharmaceutical, modern biotech pharmaceutical, natural drug extraction, nutritional healthcare products, bio-energy and biochemicals. In 2007, NCPC achieved sales revenue of RMB 6.42 billion.
May 4, 2009 British Plastics & Rubber
Further investment by DSM
as it waits to sell its rubber businesses
Capacity for Sarlink, the thermoplastic vulcanisate（架橋型エラストマー：TPV) business which DSM currently has up for sale alongside its EPDM business, has been doubled with the official opening of a new production unit at Genk in Belgium.
According to Sarlink business unit director and president David Huizing: "The TPV market is growing at rates beyond GDP growth, and Sarlink is growing much faster than that." Production capacity fell below demand in 2007, and since then the business has invested steadily in new capacity and new capabilities. The new Genk plant is fully automated and doubles (undisclosed) global capacity ? Sarlink also has a plant in Leominster, Massachusetts in the USA.
It was in 2007 that DSM announced that its elastomers businesses were to be sold off as part of the group's Vision 2010 plan to convert from an industrial chemicals company to a specialist in life science technologies. Despite its plans to get rid of them, DSM is continuing to invest in the development of its elastomer businesses and as well as this expansion of Sarlink capacity, its has been putting money into a new breed of EPDM, its Keltan ACE - Advanced Catalyst Elastomer. ACE has a high VNB (5-vinyl-2-norbornene) content which gives the EPDM a greater affinity for peroxide and so improves the curing process and the quality of the final elastomer, or can lower the hydrocarbon content of the compound and so improve oil resistance. ACE was revealed in 2007 and the first grade has now gone into production at Geleen in the Netherlands. The Keltan DE 8270C grade is intended for peroxide curing applications where it can reduce the level of peroxide needed, lowering costs and improving resistance to ageing with lower levels of residual peroxide.
架硫ゴムと熱可塑性樹脂の特長を有するエラストマーです。 射出、押出、プロー成形などさまざまな成形加工が行えます。 広範囲の硬度のグレードがあり、お客様のニーズにお答えします。 サーリンクはDSM社が製造し、東洋紡が販売しております。 ..
September 27, 2007
DSM plans elastomers
DSM is planning to dispose of its elastomers and thermosets businesses as part of an accelerated move into life sciences and performance materials. In a restatement today of its Vision 2010 strategy DSM outlined a plan to move 'non-core' businesses into separate units for divestment.
In a strategy not unlike that pursued by Bayer over the past five years DSM is positioning itself in the nutrition, pharmaceutical and performance materials businesses in sectors where it has market-leading positions, and where it can build on its strengths in chemistry, process technology, biotechnology and materials science.
'Those businesses which do not fit with the strategic thrust will be carved out and divested, during the course of the Vision 2010 period, to new owners for whom there is a stronger strategic fit and under whose ownership they can prosper further,' says the company in today's announcement.
Initially these businesses will be grouped in a new Base Chemicals & Materials cluster and include:
Melamine, urea, fertilisers and energy, currently within Industrial Chemicals and with around Eur 700 million sales in 2007;
elastomers, currently within Performance Materials and with some Eur 500 million sales this year;
special products (Nutrition, Eur 100 million);
and maleic anhydride and its derivatives (Pharma, Eur 75 million).
DSM Fibre Intermediates, currently within Industrial Chemicals and which provides backward integration for DSM Engineering Plastics, will join a new division Polymer Intermediates.
DSM's new structure from 2008 will be:
Life Sciences (nutrition and pharma),
Materials Sciences (performance materials and polymer intermediates), and
Base Chemicals & Materials.
The company says it
expects its 'portfolio adjustments' to be completed during the
course of the Vision 2010 programme. The aim is to derive 60 per
cent of the company's total revenues from specialty businesses,
remaining only in those businesses formerly within the Industrial
Chemicals cluster where backward-integration provides a
Alongside its planned divestments DSM will seek acquisitions in its core business areas to achieve external growth. Internally it expects to achieve an additional 1 billion in sales from innovation by 2010, and has raised its organic sales growth target to more than 5 per cent annually and increased its expectations from China by half to forecast sales in 2010 up from a $1 billion target to $1・5 billion.
Sale of its non-core businesses will give DSM a reduced presence at the Chemelot site at Geleen in the Netherlands and DSM says it will review its options how it can best support the further development of that site into a successful industrial park. In addition, it will continue to invest in its R & D campus infrastructure on the site.
DSM to sell DSM Energy to TAQA
Royal DSM N.V., the
global Life Sciences and Materials Sciences company headquartered
in the Netherlands, announces today that it has reached an
agreement with TAQA Abu Dhabi National Energy
for the sale of DSM Energie Holding B.V. (DSM Energy) for an enterprise
value of EUR 285 million. The intended sale is expected to close
in Q3 2009, subject to regulatory approvals and notifications.
The disposal consists of the participations which DSM has in oil and gas exploration and pipelines, including the 40% participation in Noordgastransport.
DSM expects to realize a book profit of approximately EUR 275 million after tax on the sale. This profit will be reported as an exceptional item in the income statement at closing. DSM Energy realized net sales of EUR 161 million in 2008.
Rolf-Dieter Schwalb, Chief Financial Officer of Royal DSM gave the following comment: “ The intended sale of the energy business is another important step in DSM’s accelerated transformation towards a Life Sciences and Materials Sciences company. As stated before, in such a company there is no place for participations in oil and gas exploration and pipelines. These participations have a much better strategic fit with TAQA. I would like to thank all DSM Energy employees for their continued support and substantial contribution.”
DSM to sell
urea-licensing business to Maire Tecnimont
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and Maire Tecnimont S.p.A., a leading international engineering and construction group headquartered in Italy, announce today that they have reached an agreement for the sale of DSM’s urea-licensing subsidiary Stamicarbon B.V. to Maire Tecnimont for a total consideration of EUR 38 million on a cash and debt-free basis. The intended sale is expected to close by Q4 2009, subject to regulatory and other customary approvals and notifications.
Stamicarbon, founded in 1947, is the world market leader in licensing urea technology with over 250 licensed urea plants located in over eighty different countries and a leading market share in new capacity. Urea, mainly used as a fertilizer, is produced from ammonia and carbon dioxide. Stamicarbon realized net sales of EUR 57 million in 2008 and an operating profit of EUR 25 million. In 2008 Stamicarbon’s operating profit was exceptionally high as a result of a number of large contracts closed during the year. The average operating profit for Stamicarbon has been approximately EUR 10 million per year over the past four years.
DSM acquires full ownership of NPC PA6 polymer facility
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and Shaw Industries Group, Inc. announce today that DSM has acquired full control of the PA6 polymerization facility of Nylon Polymer Company LLC (NPC) in Augusta (Georgia, United States). Shaw Industries and DSM Chemicals North America were previously joint venture partners in NPC.
As a result of the transaction, which has been closed, NPC is fully integrated into DSM Engineering Plastics’ activities as of 1 January 2010. Financial details and terms of the transaction will not be disclosed.
For DSM Engineering Plastics the acquisition of the full ownership of the PA6 polymerization facility is an important step in its strategy to increase its geographical footprint, including expansion into South America. It also allows the company full integration in the PA6 chain, including caprolactam, polymer and compounded products, in North America, supporting its strong commitment to key customers in the Americas. Last year, DSM opened its first PA6 polymerization plant in China, making it the only company to produce the entire PA6 chain in China. DSM inaugurates Akulon® PA6 polymer plant in China
Koen Devits, President of DSM Engineering Plastics Americas, says: "This acquisition represents a major expansion of our polymerization capabilities in the Americas. It helps us to fully exploit our strong backward integration at the Augusta site, where DSM also produces caprolactam, a key raw material for Akulon®. The acquisition is also needed to support the additional sales opportunities we have generated, especially in the automotive, furniture and packaging industries, and it illustrates DSM’s strong commitment to the Americas market."
Richard Pieters, Global Business Director Akulon® PA6, comments: “We are very excited about this acquisition as it will further reinforce our commitment to global customers who want local supply and global support. North America will remain a key specification and innovation area for DSM Engineering Plastics.”
Akulon® Polyamide 6 (PA6) is a thermoplastic with outstanding mechanical properties over a wide temperature range used in various everyday applications such as automotive, luggage, sports, electronics, packaging films, lighting and furniture. Caprolactam, produced by DSM Fibre Intermediates, is the raw material for PA6, which gives DSM a unique position as an integrated producer of the material. As a replacement of metal in various applications, Akulon® PA6 can offer weight reduction to for instance the automotive industry, resulting in lower CO2 emissions.
DSM Engineering Plastics
DSM Engineering Plastics is one of the world's leading suppliers of quality engineering thermoplastics providing customer value through sustainable solutions that reflect the DSM People, Planet and Profit strategy. DSM Engineering Plastics delivers innovative opportunities for customers who design or produce electrical applications, electronic equipment, cars, barrier packaging films as well as many mechanical and extrusion applications. These markets are served with a broad portfolio of high-performance materials including Akulon® 6 and 66 polyamides, Arnitel® TPC, Arnite® PBT and PET polyesters, Yparex® extrudable adhesive resins, and Stanyl® high heat 46 polyamides. Most recently, DSM Engineering Plastics introduced the first new polymer of the 21st century: Stanyl® ForTii™. DSM Engineering Plastics had sales in 2008 of EUR 761 million with 1500 employees worldwide. More on: www.dsmep.com.
DSM and Novomer to develop first CO2-based resin for coatings
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and Novomer Inc., based in Waltham (Massachusetts, United States), today announce that they have signed an agreement to jointly develop a revolutionary coating resin using carbon dioxide (CO2) as a raw material.
This development agreement follows a cooperation agreement and an investment by DSM Venturing in Novomer in 2007. The joint development project will benefit from the broad variety of DSM’s technologies and market access, in combination with the unique, efficient CO2 polymerization technology of Novomer.
The chemistry and process technology for producing polymers from CO2 and propylene oxide (PO) will be developed by Novomer, while DSM will convert the polymers into resins and formulate them for target applications such as coatings, adhesives and graphic arts. Initial results are encouraging and suggest that this project might lead to completely new and improved application properties in coatings.
Given the fact that up to 50% by weight of CO2 is used as raw material, the production of these resins will result in an improved carbon footprint. The process is also expected to be highly efficient, enabling the replacement of conventional resins in a number of coating applications.
Polycarbonate resins are widely known because of their superior performance and resistances and theoretically could find use in many types of coatings. Commercial use of conventional types has however always been limited due to their cost position and some weaknesses that are inherent in these products. The new CO2-based aliphatic 脂肪族 polycarbonates to be developed by DSM and Novomer could potentially resolve these weaknesses.
Rob van Leen, Chief Innovation Officer of DSM, comments: “DSM and Novomer are looking to develop the first polymer in more than a decade to enter the mainstream of the coating industry. This exciting development can lead to a breakthrough that could change the coating industry. Besides cost issues, these innovative coating resins also address environmental and performance issues. They therefore fit in perfectly within DSM’s People, Planet and Profit approach.”
Peter Shepard, Vice President of Business Development of Novomer, adds: “We are very enthusiastic about our relationship with DSM as they bring a wealth of skills and industry knowledge to help drive the commercialization of our technology in the coatings industry. In addition, this product development relationship with DSM leverages our ongoing technical development work that has been supported by the New York State Energy Research and Development Authority.”
Novomer (www.novomer.com) is a revolutionary new materials company pioneering a family of low-cost, high-performance, sustainable plastics, polymers and other chemicals. Based on the pioneering catalyst work of Dr. Geoff Coates at Cornell University, Novomer's groundbreaking technology allows carbon dioxide and other renewable feedstocks to be cost-effectively transformed into polymers, plastics and other chemicals for a wide variety of industrial markets. Novomer’s products combine environmental benefits with improved performance and can be used in a range of applications, from injection molded parts, specialty binders for electronics, polymeric packaging materials to paper coatings and medical implants.
IT SOUNDS TOO GOOD to be true. Ithaca, N.Y.-based start-up Novomer has a technology that reacts carbon dioxide with other molecules, locking it into a polymer backbone and putting it to better use than as an atmosphere warming gas. The company says the anti-greenhouse-gas bonus of its chemistry has drawn attention, but it would rather focus its efforts on making polymers that people want to buy.
At the heart of Novomer's technology are catalysts developed by Geoffrey W. Coates, a chemistry professor at Cornell University. The catalysts are based on transition metals and can break open the highly stable CO2 molecule, enabling it to polymerize with epoxide groups. For example, CO2 combines with ethylene oxide to make the polymer polyethylene carbonate and with propylene oxide to make polypropylene carbonate. These polymers have about 50% and 43% CO2 content by weight, respectively.
Novomer is bringing multiple products to market based on our platform of CO2 and CO catalysis technology. As our first commercial product NB-180 utilizes CO2 feedstocks to produce an ultra-performance material for specific high-tech markets.
Through cutting-edge green chemistry initiated at Cornell University, Novomer's first product NB-180 has been developed specifically for high performance industrial and commercial applications requiring a binder that decomposes rapidly, cleanly and is environmentally friendly.
NB-180 is an amorphous, colorless thermoplastic polymer (polypropylene carbonate) which decomposes into environmentally benign products making it the perfect solution for broad applications in the electronics, brazing and ceramics industries.
Due to a recently-patented catalytic process, NB-180 binders burn more uniformly and at lower temperatures than currently available sacrificial binders. Thus shorter binder burnout times and higher precision results in multiple applications can be achieved simultaneously.
DSM to sell Sarlink unit
to Teknor Apex
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that it has reached an agreement regarding the sale of the business unit Thermoplastic Elastomers (Sarlink), part of the business group DSM Elastomers, to Teknor Apex Company. The intended sale is expected to close in Q4 2010, subject to regulatory and other customary approvals and notifications.
The intended sale of the business unit is a result of DSM’s ambitions to focus on Life Sciences and Materials Sciences. As announced in September 2007, DSM Elastomers (Sarlink and Keltan) does not fit with this focus.
With a market share of around 16%, DSM Elastomers is one of the global market leaders in EPDM (Ethylene Propylene Diene Monomer) rubber under the brand name Keltan®. It is also the number two player in the market for EPDM-based - fully vulcanized 加硫処理- thermoplastic elastomers (TPVs). DSM sells these TPVs under the brand name Sarlink®.
Keltan® EPDM is used in cars and other transportation vehicles, white goods, various industrial products and construction materials and as a motor-oil additive. It is also used as a waterproof covering for roofs.
Sarlink® TPVs are used in a wide variety of applications including automotive, consumer electronics, electrical, food, building, medical and industrial applications.
Production plants for Keltan® are based in Sittard-Geleen (Netherlands) and Triunfo (Brazil). Plants for Sarlink® are found in Genk (Belgium) and Leominster (Massachusetts, United States).
A new EPDM unit with annual production capacity of 80,000 tonnes was opened by DSM Elastomers in Geleen, the Netherlands, in 2003.
2004年10月19日 Chemnet Tokyo
DSM completes sale of DSM Agro and DSM Melamine to OCI
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that it has completed the sale of DSM Agro and DSM Melamine to Orascom Construction Industries (OCI), as announced on 30 March 2010.
With the closing of the sale, OCI will start integrating the businesses as of 1 June 2010.
DSM Agro is a producer of ammonia and high-nitrogen fertilizers for grasslands and agricultural crops and the market leader in the Netherlands. It also ranks among the market leaders in Germany, France and Belgium. DSM Agro, which operates a production site in Sittard-Geleen, produces about 1.6 million tons of fertilizers per year. DSM Agro realized net sales of EUR 338 million in 2009.
DSM Melamine is the world’s largest producer of melamine. The main application of melamine is in wood-based panels and laminates used for furniture and flooring. DSM Melamine has a plant in the Netherlands and also produces melamine in joint ventures in China (DSM 49%) and Indonesia (DSM 60%). In 2009 DSM Melamine realized net sales of EUR 151 million.
Orascom Construction Industries
Over the last 50 years, OCI has grown into one of Egypt’s largest corporations with projects and investments across Europe, the Middle East and North Africa. The company directly employs more than 86,000 people.
OCI currently has two core business activities. The OCI Construction Group is a leading construction contractor active in emerging markets with a backlog of US$ 6.6 billion as at 31 December 2009. It primarily focuses on infrastructure projects in Europe, the Middle East and Africa in addition to industrial and high-end commercial projects.
The OCI Fertilizer Group is a strategic owner and operator of nitrogen fertilizer plants in Egypt and Algeria with an international distribution platform spanning Latin America, the United States, Europe and Africa.
Both parties have agreed
not to disclose financial details at this time. DSM expects to
report a small book profit as a result of the transaction upon
closing. Approximately 90 employees will transfer to the new
owner upon closing.
Sarlink(R) has compounding operations in Leominster (Massachusetts, United States) and Genk (Belgium). While the business unit will operate as an integral part of Teknor Apex, it will continue to sell its TPVs (thermoplastic vulcanizate) under the Sarlink(R) name. In 2009 Sarlink realized net sales of over EUR 50 million.
Nico Gerardu, Member of the DSM Managing Board and responsible for the Base Chemicals and Materials cluster, commented: “The sale of Sarlink is another important step for DSM in its ongoing transformation towards a Life Sciences and Materials Sciences company. As there is a natural fit with Teknor Apex, we see a bright future ahead for Sarlink under new ownership. I would like to thank all Sarlink employees for their ongoing support and substantial contribution to DSM.”
Bertram M. Lederer, executive vice president of Teknor Apex said: “Teknor Apex is a good home for the Sarlink group, and the enhanced potential from our combined people and resources will benefit customers. The addition of the Sarlink TPV business strengthens the position of Teknor Apex as the world’s most diversified independent compounder of TPEs and expands our portfolio at the high-performance end, particularly for automotive applications.”
Sarlink is one of the two business units of the business group DSM Elastomers. The selling process for Keltan (EPDM), the other business unit of DSM Elastomers, as well as most of the remaining other businesses in Base Chemicals and Materials is ongoing.
Teknor Apex Company
A privately held firm founded in 1924. Teknor Apex Company is an international polymer technology company and one of the world’s leading custom compounders of plastics. For U.S. markets, the company also manufactures chemicals such as plasticizers and the nationally branded consumer product, Apex garden hose. Teknor Apex is headquartered in Pawtucket, RI, U.S.A., operates manufacturing facilities around the world, and sells in 90 countries. Six of the eight Teknor Apex business units focus on plastics compounding, including bioplastics; color concentrates; nylon, PET, and other engineering thermoplastics; thermoplastic elastomers; toll and specialty compounds; and vinyl. The company’s operations in the U.S. serve customers throughout the Americas. Subsidiaries in China, Singapore, and the United Kingdom serve customers in Asia, Africa, the Mideast, and Europe. Visit www.teknorapex.com.
2007/5/12 米コンパウンド会社 Teknor Apex、中国進出
1949年に塩ビコンパウンド生産、塩ビホース生産から Lawn and Garden 事業
シンガポールのSingapore Polymer Corporation （SPC）を買収
英国と米国でエンジニアリング樹脂コンパウンドを供給する英国のChem Polymer を買収
DSM to acquire Martek to add new Nutrition growth platform
|*||DSM to offer US$31.50 for each share of Martek Biosciences Corporation in an all-cash transaction (through a tender offer)|
|*||Total consideration of US$1,087 million (about Euro829 million)|
|*||Offer price represents 35% premium to Martek’s closing share price on December 20, 2010|
|*||Martek Board of Directors recommends the offer|
|*||Acquisition adds new growth platform for natural, healthy Polyunsaturated Fatty Acids (PUFAs 多価不飽和脂肪酸) nutrition ingredients (Omega-3 DHA and Omega-6 ARA)|
|*||PUFAs are clinically proven to have important human health benefits. Martek is a leader in this field with strong positions, especially in Infant Formula Nutrition applications|
|*||Acquisition positions DSM as a leader in PUFAs and in Infant Nutrition, greatly strengthens DSM’s presence in the United States and expands DSM’s complementary technology platform in the field of algal and other microbial fermentations|
|*||Martek’s growth will be accelerated by DSM’s global market reach, technology base and application skill capabilities, its insights in the food, beverage and global dietary supplements markets and its strength in industrial biotechnology and related applications|
|*||Acquisition is immediately EPS(EPS accretive) accretive|
Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million. The transaction has been approved by DSM’s Supervisory Board and is recommended by Martek’s Board of Directors. Subject to customary conditions, the tender process is expected to close in February 2011, and the transaction is expected to close in the first or second quarter of 2011.
The agreed price
represents a premium of 35% to Martek’s closing share price of US$23.36
on December 20, 2010, and 39% to the volume weighted average
closing price of Martek’s common stock over the last 90
The acquisition is structured as an all-cash tender offer for all the outstanding shares of Martek common stock to be followed by a merger in which each remaining share of Martek common stock would be converted into the same cash per share price paid in the tender offer. The tender offer is expected to commence between 10 January 2011 and 25 January 2011. The Martek Board of Directors has recommended that Martek stockholders accept the offer and tender their shares into the offer when it is made. The acquisition is subject to the satisfaction of customary conditions, including the tender of a majority of the outstanding shares of Martek common stock on a fully-diluted basis and the expiration or earlier termination of the Hart-Scott-Rodino antitrust waiting period and other regulatory approvals. The tender process is expected to close in February 2011, and the transaction is expected to close in the first or second quarter of 2011.
The transaction is not subject to a financing condition, and DSM intends to finance the acquisition from existing cash.
The purchase by DSM of Martek, a U.S. based producer of high value products from microbial sources that promote health and wellness through nutrition, will be the first major acquisition by DSM after its successful transformation into a Life Sciences and Materials Sciences company. This transaction is fully in line with DSM’s strategy for its Nutrition cluster “continued value growth” and adds a new growth platform for healthy and natural food ingredients for infant formula and other food and beverage applications, especially focused on Polyunsaturated Fatty Acids (PUFAs) such as microbial Omega-3 DHA (docosahexaenoic acid) and Omega-6 ARA (arachidonic acid).
There is significant, broad based scientific evidence about the link between health and nutrition. PUFAs have been clinically proven to have a positive impact on human health and Martek is a leader in this field. Martek therefore represents an attractive strategic acquisition for DSM. It will provide DSM with new opportunities in the infant nutrition segment as well as food and beverage and dietary supplements and create a strong platform for DSM to enter the fast growing Omega-3 and Omega-6 market through Martek’s microbial DHA and ARA products.
DSM will be able to leverage DSM’s global nutritional infrastructure (global market reach, application skills, R&D and manufacturing technology base) to channel and accelerate the growth of these products into other regions, applications and market segments beyond Martek’s current strong US-based position in infant formula ingredients and growing position in food and beverage and dietary supplement applications. As a result of the scale and resources that DSM can bring to the already solid businesses of Martek, DSM instantly becomes a leading player in the field of microbial PUFAs and through this attractive growth segment expects to drive compelling financial performance for its shareholders. The acquisition is immediately EPS accretive for DSM by 15 to 20 euro cents per ordinary share on a full year basis.
The two companies already have a longstanding relationship as DSM supplies Martek with the key base material for its ARA product. DSM has complementary intellectual property to the broad range of patents and intellectual property Martek owns, which will further extend the competitiveness of the combined company’s proprietary products.
DSM will also benefit from Martek’s recent acquisition of Amerifit, an attractive consumer business for branded dietary supplements with very specific health benefits, which it will be able to use as an additional marketing channel for both Martek as well as DSM ingredients.
Furthermore, Martek’s algal and other microbial-based biotechnology platform and its robust algal technology pipeline which complements DSM’s own biotechnology portfolio, is expected to deliver new nutritional and non-nutritional (industrial) growth opportunities.
The acquisition is expected to realize material revenue synergies through expanded distribution, marketing and product development as well as other operational efficiencies, and will accelerate DSM’s revenue growth.
Martek is headquartered in Columbia Maryland USA and had annual net sales of US$ 450 million for its fiscal year which ended October 31, 2010. Martek has five principal locations and some 600 employees.
Feike Sijbesma, CEO/ Chairman of the DSM Managing Board, said:
“Martek is a great company and a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. DSM has enormous respect for Martek’s products, organization and people. We look forward to working with their highly skilled team.
“This acquisition is an attractive and logical next step for DSM. Martek’s leading position in healthy, natural ingredients and algal technology will add a new growth platform to our Nutrition business. DSM is a unique partner for Martek and, with our strong track record of growing businesses in competitive environments, we believe we can help to lift Martek to the next level.”
Martek’s Chairman, Robert J. Flanagan, said:
"We are proud of the achievements of our company and are pleased to see the company's value recognized by DSM. Following thorough analysis by our board of directors, we have determined that this transaction offers the best value for our stockholders.”
Martek’s CEO, Steve Dubin, said:
“We are pleased to announce this transaction, and we believe that it is in the best interest of Martek and our stockholders. After careful analysis, our board of directors unanimously approved this transaction with DSM, which has a strong reputation and global operations. We are pleased that this transaction appropriately recognizes the value of Martek’s nutritional ingredients, technology platform, market position and skilled workforce, while providing significant value to our stockholders. We have worked collaboratively with DSM for many years, and we are confident that they share our vision for Martek’s future.”
Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. The Company’s technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform has resulted in Martek’s development of a number of products, including the company’s flagship product, life’sDHA?, a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds. The Company also produces life’sARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. Martek’s subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: CulturelleR, a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief and detection of urinary tract infections; and EstrovenR, the leading all-natural nutritional supplement brand addressing the symptoms of menopause.
Columbia, Md.-based Martek produces polyunsaturated fatty acids - a family of nutritional supplements - via algal fermentation. Its flagship product, docosahexaenoic acid, is added to almost all major brands of infant formula, as well as to foods, beverages, and dietary supplements. Martek’s fiscal 2010 sales were $450 million, up 30% over the previous year.
In addition to fast growth, Martek brings an algal technology platform that complements DSM’s own expertise in yeast fermentation, enzymes, and advanced chemistry. In fact, Martek’s number two product, the fatty acid arachidonic acid, is manufactured under contract by DSM via fungal fermentation.
Formation of an Asian anti-infectives joint venture, meanwhile, is a long-held goal of the Dutch company, which is one of just a few remaining Western producers of penicillin. DSM had held sporadic talks with North China Pharmaceutical Group about such a venture since 2004 but finally abandoned them in 2009.
Under the new deal, Sinochem becomes half owner of a business with $425 million in annual sales and about 2,000 employees. In a presentation to investors, DSM executives said they believe Sinochem’s position as one of China’s biggest state-owned enterprises will help expand the business to more than $750 million in sales by 2015.
“Anti-infectives has been a problem child for years,” observed Andreas Heine, a stock analyst with UniCredit, in a note to investors. “The agreed move with Sinochem seems to be a very good solution.”
DSM and KuibyshevAzot
announce strategic cooperation in Russia
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and KuibyshevAzot OJSC (KA) today announce a strategic cooperation. As a result of this strategic cooperation, DSM Engineering Plastics will enter into two joint ventures with KA. In both joint ventures DSM Engineering Plastics will hold a majority share. In addition, KA will be granted a license under DSM Fibre Intermediates’ technology for the production of cyclohexanone.
The two joint ventures of DSM Engineering Plastics and KA relate to marketing and sales of engineering plastics in Russia and other members of the Commonwealth of Independent States (CIS) and secondly for the production of engineering plastics compounds in a plant located in Togliatti (Russia). The strategic cooperation between DSM and KA will also result in a license grant under DSM’s proprietary cyclohexanone technology to be applied at KA’s Togliatti caprolactam plant, resulting into a further increase of its capacity to meet the growing demand for this polyamide 6 intermediate.
Nico Gerardu, Member of the DSM Managing Board and responsible for the Performance Materials cluster, commented: “This strategic cooperation with KA is another example of DSM’s commitment to expansion in High Growth Economies through Acquisitions & Partnerships, two of the four growth drivers of our corporate strategy DSM in motion: driving focused growth. We are excited to be able to partner with KA, one of Russia’s leading companies in the intermediates industry. Russia is an increasingly important market for engineering plastics and it is expected that the market for PA6 will double in the next five years. With our partnership with KA I expect that DSM Engineering Plastics will be in an excellent position to capitalize on this anticipated growth. Furthermore, I see the license agreement for cyclohexanone as further recognition of our technology leadership.”
Victor Gerasimenko, General Director of KuibyshevAzot OJSC, said: “Cooperation with DSM will promote the realization of our strategic plans to strengthen our leading positions in the markets for caprolactam and polyamide and to increase the processing of these products within Russia. The use of technology from leading global licensors will allow us to increase operational performance and long-term competitiveness.”
DSM Engineering Plastics and KA are joining forces in a marketing and sales joint venture to better capture opportunities in the growing market for engineering plastics in Russia and other countries in the region. The joint venture will concentrate on polyamide 6 (PA6), both compounds and high viscosity applications including film. DSM Engineering Plastics will hold a 51% stake in the joint venture.
DSM Engineering Plastics also intends to acquire 80% in the engineering plastics compounding plant located on KA’s manufacturing site in Togliatti. As such, DSM will be the first western PA6 supplier with its own manufacturing presence in Russia and the CIS. Financial details and capacity of the plant will not be disclosed.
As a result of the license agreement between DSM and KA, DSM will realize royalty income over 15 years. DSM Fibre Intermediates will also participate via drawing rights in part of the increased production capacity of KA.
DSM has proprietary world-class cyclohexanone and caprolactam technologies with multiple licensees worldwide.
The establishment of the joint ventures and related agreements is subject to regulatory approval. Closing of the intended acquisition of the compounding plant is expected in Q1 2011.
KuibyshevAzot OJSC is one of the leading companies of the Russian chemical industry. The company located in Togliatti, Samara region, conducts its business in two areas: production of caprolactam and its derived products (PA-6, high tenacity yarns, cord fabric, engineering plastics) ;production of ammonia and nitrogen fertilizers. KuibyshevAzot takes a leading position in output of caprolactam and polyamide in Russia and CIS and is among the top ten major global producers of these products. The company consistently builds up the proportion of higher added value product, by realization from 2003 projects for further caprolactam processing. In 2009 the company realized net sales of RUB 16,039 million ($ 505.2 million with 5,300 employees. The official web site www.kuazot.ru.
ＤＳＭはロシアでポリアミド（ＰＡ）６事業の本格展開に乗り出す。このためク イビシェフアゾドＯＪＳＣ（ＫＡ）社と提携、販売とコンパウンドの生産に関する２社の合弁会社を設立する。同時にＤＳＭがシクロヘキサノンの生産技術を ＫＡに供与、ＫＡはカプロラクタム事業の強化につなげる。両社の計画では、ＤＳＭが５１％を出資するＰＡ６のコンパウンドとフィルムのマーケティングと販 売を手掛ける合弁会社を設立する。またコンパウンドの生産については、ＫＡがサマラ州トリアッティに持つ設備を合弁で運用する。ＤＳＭが８０％を出資する 予定。生産能力は明らかにしていない。ＫＡはカプロラクタム、ＰＡ６、肥料などの事業を展開している。ＤＳＭと手を組むことによってコンパウンドの販売体 制を強化する一方、ＤＳＭからシクロヘキサノンの生産技術を導入することで、カプロラクタムとＰＡ６の競争力を高める。
“KuibyshevAzot” OJSC is one of the leading companies of the Russian chemical industry.
The company conducts its
business in two areas:
- production of caprolactam and its derived products (PA-6, high tenacity yarns, cord fabric, engineering plastics);
- production of ammonia and nitrogen fertilizers.
Besides, “KuibyshevAzot” produces process gases which meet requirements of the main business-directions and at the same time are independent commodity products.
range of products
accounts about 30 iterns.
The key figures
|Sales, RUR million||4473||16039||259%|
|Caprolactam, '000 tons||105||175,3||67% Russiaでのシェア 50%|
|Polyamide, '000 tons||0||86.6||New product|
|Technical yarn, '000 tons||0||6,3||New product|
|Tire cord fabric, '000 tons||0||5,1||New product|
|Ammonium nitrate, '000 tons||299.8||500,5||60%|
|Urea, '000 tons||193.0||312.6||63%|
|Ammonium sulphate, '000 tons||307.9||448,4||46 %|
|Ammonia, '000 tons||530.6||556,9||5 %|
|Freight turn-over, '000 tons||1353||2055,4||51.9%|
DSM acquires majority share in UHMWPE fiber manufacturer in China
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announced today that it has signed an agreement to acquire the majority shareholding in Shandong ICD High Performance Fibre Co Ltd. (“ICD”), based in Laiwu莱蕪市, Shandong province, China. Closing of this transaction is expected in the course of 2011.
Established in August 2005, Shandong ICD High Performance Fibres Co., Ltd is a high technology corporate, and is the star patent corporate in Shandong of China. With registered capital of RMB 200 million yuan, it is located in the high-tech developed industrial zone of Laiwu in Shandong province. The total area is 20 hectares, and it is a large scale modern corporate gathering research, exploit, product and sale together. If the production capacity of 5000 tons for HMW polyethylene project is realized, the corporate will be the biggest one in China and the first one in Asia and the second one in the world for production of HMW polyethylene fibres.
The acquisition of the majority share in ICD will bring complementary manufacturing and technology assets to DSM in addition to strengthening the company’s presence in this key market. The agreement with ICD, a manufacturer of UHMWPE (ultra high molecular weight polyethylene) fiber and a potential strong player in the Chinese market for high performance fibers, concludes an extensive selection process by DSM to find the right company in the Chinese market.
This strategic step underlines DSM’s commitment to its sales growth and strategic objectives in China and reflects its policy of acquiring businesses with strong potential and a proven track record of success. The acquisition of the majority share in ICD also fits in DSM’s corporate strategy DSM in motion: driving focused growth with expansion in High Growth Economies as one of the growth drivers.
Nico Gerardu, member of the DSM Managing Board and responsible for DSM’s Performance Materials cluster said: “China is a key market for DSM and we will continue to grow our long term commitment to it. We have invested significant time and effort to identify the right partner to ally with for this acquisition and we are extremely excited about the prospect of bringing ICD into the DSM portfolio.”
Gerard de Reuver, President of DSM Dyneema, added: “China is an important market in terms of both UHMWPE fiber production and consumption and this announced acquisition further develops our position and will help us grow and succeed in this market. This move strengthens our position to better serve our Chinese customers and builds on the long standing success of DSM’s investments in China."
Ren Yi, General Manager of ICD, commented: “This is an exciting development for everyone at ICD and I believe it will help to secure our future growth and success in the Chinese UHMWPE fiber market. We expect to benefit significantly from DSM’s global know-how, operating standards and technical expertise which will help us enhance our ability to serve our customers and develop new markets and application opportunities in China.”
For DSM, the acquisition of a majority share in ICD represents a key milestone in the global development of its high performance materials business, DSM Dyneema. The parties have agreed not to disclose the financial terms of this transaction.
Sinopec and DSM build
100kt/a Composite Resin Project in Nanjing
On May 13, 2011, Sinopec Jinling Petrochemical and DSM held a ground breaking ceremony for their new jv composite resin project in Nanjing Chemical Industry Park, Nanjing, Jiangsu Province.
With total investment RMB 643 million, the project will has designed capacity of 100 kt/a of unsaturated polyester resin (UPR).. The new project is expected to come on stream in early 2012.
The project will be operated by Jinling DSM Resins Company (JDRC) - a 75:25 jv between DSM and Sinopec. JDRC was founded in 1989. Now it is the leading special UPR and Vinyl ester resins producer.
Project name: Jinling DSM 100 kt/a Composite Resin
Location: Nanjing Chemical Industry Park
Company Jinling DSM Resins Company
Capacity: 100 kt
Investment: 6.43 million RMB (including the environmental protection 19.7 million)
Area: 80000 m2
In Jinling in Nanjing City, JDRC has an existing resin plant with capacity of 35 kt/a. According to the planning of Nanjing Government, the existing small plant will be closed with the replacement of new project starts up.
Also in NCIP, DSM Nanjing Chemical Company (DNCC) - the 60:40 jv between DSM Fibre Intermediates and Sinopec Nanjing Chemical Industries Company is operating a 200 kt/a CPL plant.
江蘇省はDSMの中国ビジネスの中心で、南京市のほか、江陰市（DSM Engineering Plastics Jiangsu)、昆山市（DSM Eternal Resins Kunshan)、無錫市（DSM Citric Acid Wuxi 及び Wuxi Nutririce)に製造拠点を持っている。
According to the regulations released by China's State Administration of Work Safety （国家安全生産監督管理総局：SAWS） in Nov. 2010, in order to strengthen the chemical safety management, the new chemical projects must be built in the Chemical Industry Park.
For the chemical producers, the Jiangsu local Government asks all the existing plants (if produce dangerous chemicals or use dangerous chemicals as feedstock) move to the chemical parks step by step.
July 04 2011
DSM and KuibyshevAzot commence strategic cooperation in Russia
Royal DSM N.V., the global Life Sciences and Materials Sciences company, and KuibyshevAzot OJSC (KA) today announce they have commenced their strategic cooperation, as announced in January 2011. As a result of this strategic cooperation, DSM Engineering Plastics has two joint ventures with KA. In both joint ventures DSM Engineering Plastics holds a majority share. In addition, KA has received a license under DSM Fibre Intermediates’ technology for the production of cyclohexanone.
The two joint ventures of DSM Engineering Plastics and KA relate to marketing and sales of engineering plastics in Russia and other members of the Commonwealth of Independent States (CIS) and secondly for the production of engineering plastics compounds in a plant located in Togliatti (Russia). The strategic cooperation between DSM and KA relative to engineering plastics has also resulted in a license grant under DSM’s proprietary cyclohexanone technology to be applied at KA’s Togliatti caprolactam plant, resulting into a further increase of its capacity to meet the growing demand for this polyamide 6 intermediate.
DSM Engineering Plastics and KA are joining forces in a marketing and sales joint venture to better capture opportunities in the growing market for engineering plastics in Russia and other countries in the region. The joint venture concentrates on polyamide 6 (PA6), both compounds and high viscosity applications including film. DSM Engineering Plastics holds a 51% stake in the joint venture.
DSM Engineering Plastics also acquired 80% in the engineering plastics compounding plant located on KA’s manufacturing site in Togliatti. As such, DSM is the first western PA6 supplier with its own manufacturing presence in Russia and the CIS. Financial details and capacity of the plant will not be disclosed.
As a result of the license agreement between DSM and KA, DSM will realize royalty income over 15 years. As consideration for the license, DSM Fibre Intermediates has further obtained drawing rights on part of the increased production capacity of KA. DSM has proprietary world-class cyclohexanone and caprolactam technologies with multiple licensees worldwide.
KuibyshevAzot OJSC is one of the leading companies of the Russian chemical industry. The company located in Togliatti, Samara region, conducts its business in two areas: production of caprolactam and its derived products (PA-6, high tenacity yarns, cord fabric, engineering plastics) and production of ammonia and nitrogen fertilizers. KuibyshevAzot takes a leading position in output of caprolactam and polyamide in Russia and CIS and is among the top ten major global producers of these products. The company consistently builds up the proportion of higher added value product, by realization from 2003 projects for further caprolactam processing. In 2009 the company realized net sales of RUB 16,039 million ($ 505.2 million with 5,300 employees. The official website: www.kuazot.ru.
the total design capacity of the company be 150,000 t of PA6 per year.
ammonia plant capacity rose up to 1,740 tons.
12 July 2011 DSM
DSM successfully acquires 51% stake in AGI Corporation (Taiwan)
Royal DSM N.V., the global Life Sciences and Materials Sciences company, today announces that it has successfully acquired a 51% stake in AGI Corporation of Taiwan (AGI) through a subscription for newly to be issued shares combined with a public tender offer for about Euro 41 million in total. The acquisition was announced in December 2010 and is consistent with DSM’s strategic focus on high growth economies, sustainability, innovation and partnerships.
AGI offers a broad range of environmentally friendly UV (ultraviolet) curable resins and other products. These products are used in coatings and inks for wood, flooring, plastic and graphic arts applications. AGI reported net sales in 2010 of NTD 4,050 million (approximately Euro 97 million). AGI continues to be listed on the emerging companies board of the GreTai Securities Market in Taipei. DSM will consolidate AGI in its financial statements.
Dimitri de Vreeze, President of DSM Resins & Functional Materials, commented: “The acquisition of 51% of AGI allows DSM to strengthen its UV resins technology platform. UV curing is environmentally friendly and the winning technology for the future. UV coatings and ink systems have a low eco-footprint in combination with high-performance low total operational costs. This expansion in UV coatings and ink system markets will allow DSM to realize its ambition to become the global leader in sustainable and innovative resins, the key ingredients of paints and inks. We look forward to working with AGI and its shareholders, management and employees.”
Bill Chung, Chairman of AGI Corporation said: “We are looking forward to work with DSM to provide better services to the market and grow the UV business together. DSM and AGI share the same dream of being a leading UV player fulfilling the needs of our customers with a winning and innovative technology toolbox. Via this strategic alliance strong momentum will be created to realize this dream. AGI is a strong Asian company and has in depth knowledge about the high growth economies in this part of the world. This combined with DSM’s global market know how and asset infrastructure creates a unique combination. Being complementary to each other, we are confident that DSM-AGI is going to generate a compelling, and high-potential future for AGI’s customers, shareholders and employees.”
30 September 2011 DSM
DSM completes acquisition of majority share in China-based UHMWPE fiber manufacturer
Royal DSM N.V. (DSM), the global Life Sciences and Materials Sciences company, today announced that it has successfully completed the acquisition of a majority share of 91.75% in Shandong ICD High Performance Fiber Co. Ltd. (ICD 山東愛地高分子材料), based in Laiwu 莱蕪市, Shandong province, China, as announced on 17 February 2011. Financial terms of the acquisition are not disclosed.
ICD is a manufacturer of UHMWPE (ultra high molecular weight polyethylene) fiber and a strong player in the high-performance fiber market in China. The acquisition brings complementary manufacturing and technology assets to DSM and substantially strengthens the company’s presence in this key market.
Nico Gerardu, member of the DSM Managing Board and responsible for DSM's Performance Materials cluster, commented: "We are delighted to have completed this acquisition and we welcome ICD to DSM. This acquisition reflects our continued commitment to China and our strategy of investing in High Growth Economies as well as in partners with proven success and high growth potential.”
Gerard de Reuver, President of DSM Dyneema, added: "China is a major market for UHMWPE fiber production and consumption. This acquisition marks a milestone in the global development of DSM Dyneema and provides a stronger platform for continued growth and leadership in the China market.”
Ren Yi, General Manager of ICD, said: "We are excited to be joining DSM and believe this will secure long term success and growth for us in China. Our local knowledge together with DSM’s global standards and expertise will help improve our customer service and boost market and application development opportunities.”
Established in August 2005, Shandong ICD High Performance Fibres Co., Ltd is a high technology corporate, and is the star patent corporate in Shandong of China. With registered capital of RMB 200 million yuan, it is located in the high-tech developed industrial zone of Laiwu in Shandong province. The total area is 20 hectares, and it is a large scale modern corporate gathering research, exploit, product and sale together. If the production capacity of 5000 tons for HMW polyethylene project is realized, the corporate will be the biggest one in China and the first one in Asia and the second one in the world for production of HMW polyethylene fibres.
超高分子量ポリエチレンは、エンジニアリングプラスチックの一種で、非常に高い耐衝撃性と強度を持ち、耐切創性、耐摩耗性、耐薬品性にも 優れている。主として繊維やテープなどの形状で使用され、その特性を生かして、強化プラスチックをはじめ、防護・防弾・防刃製品、ロープ、ネット、医療 分野など、幅広い用途への展開が可能とされる。
Guangdong Shinda UHMWPE Fiber Co.はポリエステルチップの最大の企業の一つ。
2005 QuadrantがPoly Hi Solidur買収
（world market leader in UHMW-PE products）
三菱樹脂とQuadrant の創業者4人が、オランダに50/50の合弁形態での持株会社Aquamit B.V.を設立し、この持株会社がQuadrant の株式の公開買付けを実施し、100%を取得
DSM Nanjing Chemical Company, Ltd.
東洋エンジニアリング株式会社(TOYO 取締役社長 山田 豊)は、DSM 社とシノペックグループとの合弁会社であるDSM Nanjing Chemical Company, Ltd.から、カプロラクタム製造設備プロジェクトを受注しました。本プロジェクトは、中国・南京において生産能力年産20 万トンのカプロラクタム製造設備を新設するものです。同社は南京に年産20 万トンのカプロラクタム製造設備を保有しております。本プロジェクトの完成により同社の南京のカプロラクタム生産量は40 万トンとなり、完成後は世界最大の生産能力を持つ設備となります。当社はランプサム契約にてプラントの設計、調達サービス、工事管理を実施し、プラントの完成は2013 年第２四半期を予定しています。なお客先の投資金額は約3 億ドルです。
DSM 社は、ナイロン繊維(ナイロン6)やナイロン樹脂、フィルムの原料となるカプロラクタムを主力商品としており、欧州、北米、中国にプラントを持ち、現在合計で約70 万トンの生産能力を持っています。
TOYO は、中国における40 年の経験に加え、Toyo-China を中心とした現地リソースを有効に活用し、今後も第三国企業の中国へのプラント建設を支援し、同国での受注活動を展開していきます。
客先 DSM Nanjing Chemical Company, Ltd.
（DSM 社、Sinopec Nanjing Chemical、Jiangsu Guoxin Groupの共同出資会社）
建設地 中国 江蘇省 南京市
対象設備 カプロラクタム製造設備（年産 20 万トン）
完工時期 2013 年度第２四半期の予定
Nov 12, 2012 DSM
DSM to sell participation in DEXPlastomers JV
Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has reached an agreement with Borealis AG for the sale of DEXPlastomers V.o.F, a 50/50 Joint Venture of DSM with an affiliate of ExxonMobil Chemical. DSM will also sell its LldPE Compact Solution Technology to Borealis. Subject to customary approvals and notifications, the transaction is expected to close in Q1 2013.
Established in 1996, DEXPlastomers is a 50/50 joint venture between DSM and Exxon Chemical Holland Ventures B.V., producing C8 plastomers and linear low density polyethylene. DSM’s LldPE Compact Solution Technology was developed in the 1960’s to produce polyethylenes in a certain density range and is instrumental to the operations of DEXPlastomers.
A 50 / 50 joint venture between DSM and ExxonMobil Chemical.
Established in 1996.
Two product families, Exact™ Plastomers and Stamylex™ octene linear polyethylenes.
120 kTpa solution PE capacity.
In 2012, DEXPlastomers anticipates sales of
approximately €180 million. Currently, 95 DSM employees are in the scope of the
For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials. DSM’s 50% participation in DEXPlastomers is reported under Corporate Activities in DSM’s accounts.
Borealis to acquire DEXPlastomers
Borealis, a leading provider of chemical and innovative plastics solutions, announced today that it has reached an agreement to acquire the shares of DSM Plastomers B.V. and Exxon Chemical Holland Ventures B.V., each holding a 50% interest in DEXPlastomers V.O.F. in Geleen, The Netherlands, from DSM Nederland B.V. and ExxonMobil Benelux Holdings B.V. DEXPlastomers is a 50/50 Joint Venture ultimately owned by Royal DSM and ExxonMobil Chemical Company.
Following this agreement, the relevant employee representatives are being informed and consulted on the proposed sale to Borealis. The transaction is subject to customary approvals and notifications.
The products of DEXPlastomers are specialties complementary to Borealis' current innovative plastic solutions. The agreement made with ExxonMobil Benelux Holdings B.V. and DSM Nederland B.V. underpins Borealis' commitment to its Value Creation through Innovation strategy, as Borealis believes there is significant potential in DEX-Plastomers’ technology.
NewCo will have an end-to-end offering from finished dosage (drug products) to active substances (APIs) and a global footprint of 23 locations across North America, Europe, Latin America and Australia with about 8,300 employees.
Combining DPP and Patheon is fully in line with DSM’s strategy for its Pharma cluster as well as an excellent value creation opportunity as DSM and JLL will work together to maximize the value of NewCo. For DSM, combining DPP with Patheon into NewCo is also a key step in the strategic transformation of its Pharma activities into partnerships.
Once the transaction is complete, NewCo will add scale and new value chain capabilities/technologies to expand its end-to-end service offering as a comprehensive solution provider to the industry. NewCo will operate as an independent standalone company.
The highlights of the transaction are as follows:
Patheon is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, with a focus on drug products. In the 12 months ending 31 July 2013, the company recorded revenues of USD 943 million and pro-forma consolidated EBITDA (per credit agreement definition) of USD 188 million. The company has around 5,900 employees.
DPP is a leading provider of contract development and manufacturing services to the pharmaceutical, biopharmaceutical and agrochemical industries with a focus on drug products and APIs. In 2012 DPP realized net sales of €543 million with around 2,400 employees.
NewCo will have a unique breadth of service offerings with a focus on drug products and APIs with a wide range of technologies and will be able to offer comprehensive end-to-end solutions to a broad spectrum of companies ranging from large pharmaceutical and biotech companies to specialty pharma companies, generics and emerging pharma companies.
The combined company will also be a leader in proprietary softgel formulations for over-the-counter, prescription and nutritional consumer products. The exclusive synthesis products and intermediates are targeted to the crop protection, personal care, and fine chemicals products industries.
Jim Mullen, currently CEO of Patheon, will be appointed CEO of NewCo upon completion of the transaction. Mr. Mullen joined Patheon in 2011 as Chief Executive Officer. Prior to joining Patheon, he served as CEO and President at Biogen Idec Inc., one of the world's largest biotechnology companies from 2003 to 2010. He possesses over 30 years of industry experience, ranging from biotechnology and pharmaceuticals to specialty chemicals, as well as extensive expertise in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions.
Feike Sijbesma, CEO and Chairman of the DSM Managing Board, said: “Fully in line with our strategy, this is for DSM Pharmaceutical Products the perfect way to accelerate growth and for DSM to maximize value for this business. By creating a global top CDMO organization I am convinced that NewCo as a standalone company will be able to create substantial value. With this partnership DSM has made a key step in the strategic transformation of its Pharma activities into partnerships whilst creating maximal value for all stakeholders.“
Paul S. Levy, Managing Director of JLL Partners, Chairman of the Board of Patheon shared: “This partnership demonstrates JLL’s commitment to building companies that create value, fill unmet needs and drive excellence within their respective industries. This is the strategic initiative and execution ‘know how’ that stakeholders have come to expect from JLL. NewCo is poised to transform the CDMO industry and we are excited to bring these two entities together.”
Stefan Doboczky, Member of the DSM Managing Board and responsible for the Pharma cluster, commented: “Our customers bring life-saving and life-enhancing medicines to people who need them around the world. They will greatly benefit from NewCo’s unmatched depth and breadth of capabilities and services. I am convinced that NewCo will be even better positioned to help customers succeed with their unique needs.”
Jul 11, 2014
DSM to acquire Aland (China) to strengthen
vitamin C position
Royal DSM, the global Life Sciences and Materials Sciences company, announces today it has reached agreement to acquire Aland (HK) Holding Limited (“Aland”), a Hong Kong-based company producing vitamin C in mainland China. Financial details will not be disclosed at this time. Subject to customary conditions, the transaction is expected to close in the next six to nine months. DSM previously announced on 9 April 2014 that it was in exclusive discussions to acquire Aland.
Acquiring Aland, one of the leading Vitamin C manufacturers in China, allows DSM to further strengthen its position in vitamin C. Aland increases DSM’s global footprint in vitamins for Human Nutrition & Health, Animal Nutrition & Health and Personal Care. DSM remains fully committed to its current vitamin C manufacturing facility in Dalry (Scotland, United Kingdom). The acquisition fully meets DSM’s financial and strategic requirements.
Aland was founded in 1990 and has a production facility in Jingjiang, Jiangsu Province in China. In 2013 the company realized net sales of about USD 90 million in vitamin C with around 1,850 employees. The transaction excludes Aland’s consumer health activities. DSM plans to invest in Aland’s production facilities for operational excellence including quality and environmental performance.
Vitamin C, the world’s largest vitamin measured by volume, is an essential health ingredient that the body cannot produce itself and that needs to be absorbed through diet or supplementation. Vitamin C is widely found in fruit and vegetables. The recommended dietary allowances for vitamin C in the United States were recently revised upwards to 90 mg/day for men and 75 mg/day for women.
First commercial-scale cellulosic ethanol plant in the U.S. opens for business
Project LIBERTY converts baled corn cobs, leaves, husk and stalk into renewable fuel. The plant has now officially started up, processing its first batch of biomass into cellulosic ethanol and is moving forward toward continuous operation. At full capacity, it will convert 770 tons of biomass per day to produce ethanol at a rate of 20 million gallons per year, later ramping up to 25 million gallons per year.
Feike Sijbesma, Chief Executive Officer and Chairman of the Managing Board of Royal DSM said: “This is an historical day in the development of plant-residue-based cellulosic ethanol as a viable, commercially attractive alternative to gasoline as we are moving from the fossil age to the (bio-)renewable age. For DSM this is a strategic investment, applying our proprietary technology to convert agricultural residue on a commercial scale, allowing it to be replicated at other facilities globally as we are ramping up our cellulosic ethanol licensing business.”
“Some have called cellulosic ethanol a ‘fantasy fuel,’ but today it becomes a reality,” said Jeff Broin, POET founder and Executive Chairman. “With access now to new sources for energy, Project LIBERTY can be the first step in transforming our economy, our environment and our national security.”
This first commercial-scale cellulosic ethanol facility marks a huge step forward in the wider adoption of biofuels, both in North America and elsewhere. It is also a victory for the Renewable Fuel Standard (RFS), which prompted increased investment into advanced biofuels that accelerated development of this new technology. The RFS is a critical tool in moving the U.S. beyond 10 percent ethanol use to allow this new technology to expand to other parts of the country.
Meanwhile, in other parts of the world the development of cellulosic ethanol is expected to be boosted as POET-DSM’s Liberty process and technology to effectively convert agricultural residue using a proprietary cocktail of enzymes and yeast becomes available via licensing.
The Departments of Energy and Agriculture and the State of Iowa have been important partners in bringing this technology to commercial scale. The DOE has awarded $100 million in grants to support the costs of engineering and construction, as well as biomass collection and infrastructure. The State of Iowa has taken a lead role in helping make Project LIBERTY a reality by contributing $20 million in grants for capital costs and feedstock logistics. USDA invested $2.6 million to support the delivery of more than 58,000 dry tons of corn crop residue, helping establish the feedstock logistics network.
Assuming continued support from the RFS program and depending on the adoption rate of cellulosic ethanol both in and outside the United States, POET-DSM Advanced Biofuels LLC has the potential to achieve net sales of about $250 million from bio-ethanol and license income by 2020 with EBITDA margins clearly above average.
Fast facts about Project LIBERTY:
About POET-DSM Advanced Biofuels, LLC
POET-DSM Advanced Biofuels, LLC, is a 50/50 joint venture between Royal DSM and POET, LLC. Based in Sioux Falls, South Dakota, the company is a cooperative effort of two innovators that provides a key to unlocking the opportunity of converting corn crop residue into cellulosic bio-ethanol. Built on the strengths of both companies, the joint venture has a critical mission: to make cellulosic bio-ethanol competitive with corn bio-ethanol, the most competitive renewable liquid transportation fuel on the US market today. Drawing on the deep expertise and experience of POET and DSM in different areas of converting cellulosic biomass into bio-ethanol, POET-DSM Advanced Biofuels has built its first commercial-scale plant co-located with POET' Biorefining – Emmetsburg in Emmetsburg, Iowa. Based on this plant, the JV plans to globally license an integrated technology package for the conversion of corn crop residue to cellulosic bio-ethanol. More information: www.poetdsm.com.
POET, one of the world’s largest ethanol producers, is a leader in
biorefining through its efficient, vertically integrated approach to
production. The 25-year-old company has a production capacity in excess
of 1.6 billion gallons of ethanol and 9 billion pounds of high-protein
animal feed annually from its network of 27 production facilities. POET,
through its joint venture with DSM, also operates a commercial-scale
cellulosic ethanol plant in Emmetsburg, Iowa.
Nov 5, 2014 Bloomberg
DSM Said to Explore Sale of Chemicals Assets
Dutch chemical and ingredients company Royal DSM NV (DSM) is exploring a sale of some assets to Ineos Group Holdings Inc., according to people with knowledge of the matter.
DSM, under pressure from activist investor Third Point LLC to break up and focus on more profitable nutrition offerings, is in advanced talks with Ineos over exiting caprolactam and acrylonitrile operations, said the people, who asked not to be identified because the matter is private. The assets, which are used for synthetic fibers in clothing, carpets and car parts, generate annual sales of about 1.7 billion euros ($2.1 billion), according to estimates by Barclays.
A potential deal is still being structured, the people said. The companies may form a venture that would allow DSM to exit the chemical operations while securing supplies to feed its remaining performance materials sites, they said. An agreement is possible by year end, they said. A spokesman for DSM declined to comment, while Ineos’ spokespeople couldn’t immediately be reached.
Third Point, the hedge fund led by Daniel Loeb, advocates a break up of DSM that it says would unlock value trapped in a diverse chemical company making plastics for car parts and supplements for baby food. An Oct. 1 regulatory filing showed Third Point has accumulated a stake in DSM of more than 3 percent.
DSM shares reversed earlier losses and rose as much as 3 percent in Amsterdam intraday trading, valuing the company at 9.1 billion euros. Before today, the stock had lost 13 percent since the start of the year.
DSM Chief Executive Officer Feike Sijbesma yesterday outlined plans to dispose of units generating as much as 2 billion euros in revenue, saying his company would need to agree on accessing sufficient supplies for its own performance materials businesses.
Nutrition has been the cornerstone of Sijbesma’s strategy, absorbing the lion’s share of acquisition spending. The company spent about $3.2 billion on deals to expand in products from Omega 3 fatty acids to supplements for dairy and beef cattle.
DSM produces caprolactam in China, Europe and North America, as a feedstock for its own polymer plants as well as supplying externally. Merchant sales of caprolactam are worth about 1.2 billion euros a year to DSM, with acrylonitrile accounting for a further 500 million euros in revenue, according to a report by Barclays.
For Ineos, which turns over $47 billion a year, a deal with DSM would enhance its leading position in acrylonitrile, used in the production of synthetic fibers for clothing and carpets to car parts and phones. Higher prices for raw materials such as benzene and oversupply in the caprolactam market have depressed margins and heightened the importance of integration and economies of scale.
Ineos founder Jim Ratcliffe has built one of the world’s top 10 chemical companies in revenue in under 20 years by buying up petrochemical and plastics operations from companies including BASF SE and BP Plc.
16 Mar 2015 DSM 2007/10/3 DSMの経営方針 新社名 Fibrant
DSM and CVC announce partnership for Polymer
Intermediates and Composite Resins
DSM delivers on the strategic actions it announced for these businesses in November 2014
CVC is an experienced investor with a proven track record in the chemical industry
Royal DSM, the Life Sciences and Materials Sciences company, and CVC Capital Partners (CVC), one of the world’s leading investment advisory firms, today announced a partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins through the formation of a new company, provisionally called NewCo.
Highlights of the transaction:
・NewCo will be 65% owned by CVC and 35% by DSM, with 1,950 employees
・Pro-forma third-party sales of NewCo in 2014 amounted to €2.1 billion with a 2014 EBITDA of €106 million
・The enterprise value of the transaction is €600 million plus an earn-out of up to €175 million
・Financing of NewCo will primarily be through an equity contribution from both shareholders, third party financing and a €100 million bridge loan provided by DSM
・Estimated net cash proceeds at closing to DSM of €300-350 million
・DSM will recognize an initial book loss of approximately €130 million after tax and non-controlling interests, as an exceptional item in Q1 2015
・Closing, subject to customary conditions and approvals, is expected in Q3 2015
・DSM will contribute its global caprolactam business (Europe, North America, its 60% stake in DNCC (China) and the caprolactam licensing business),
DSM’s acrylonitrile business and
DSM’s Composite Resins business including its 75% stake in JDR (China)
・DSM’s 65% stake in the service organization Sitech Services held via its caprolactam and acrylonitrile businesses will also be transferred
・DSM Engineering Plastics has secured at least 80% of its caprolactam needs for 15 years after closing via drawing rights to secure its strategic position and competitiveness, effectively maintaining DSM Engineering Plastics’ backward integration
|中国||DSM Nanjing Chemical
|400||Jinling DSM Resins
|米国||DSM North America
(Shaw 引取権 45)
|Sitech Services 出資||19%||46%|
2011/1/5 DSM、Martek Biosciencesを買収 再構築をほぼ完成
DSM とJLL、26 億米ドルの取引で、世界をリーする医薬品サービス会社設立
DSM Pharmaceutical ProductsとPatheon Inc.が合併、医薬品メーカーに対する製剤開発・受託製造機関（CDMO）の世界的リーダーとなる。
新会社はDPxで、JLL (51%) とDSM (49%) の共同所有
|DNCC : DSM Nanjing
JDR : Jinling DSM Resins Co.
For DSM, this proposed transaction is a logical step in the execution of its strategy as Polymer Intermediates (caprolactam, acrylonitrile) and Composite Resins no longer fit with its more resilient portfolio in Nutrition and Performance Materials. The partnership with CVC allows DSM to further reduce the cyclicality of its portfolio, secure a long-term competitive supply position of caprolactam for DSM Engineering Plastics and fully focus on the Nutrition, Performance Materials and Innovation activities complemented by accelerated actions to improve efficiencies and reduce costs.
NewCo will continue to supply at least 80% of DSM Engineering Plastics’ caprolactam needs in Europe and North America for the coming 15 years via a drawing rights contract, effectively maintaining DSM Engineering Plastics’ backward integration. In China DSM Engineering Plastics will continue to be supplied by NewCo as today. This secures an ongoing strategic and competitive position for the polyamide 6 business in which DSM is a global leader.
NewCo will operate as an independent company with three business units: caprolactam, acrylonitrile and composite resins. Pro-forma third party sales of NewCo amounted to €2.1 billion in 2014 with an EBITDA of €106 million, excluding non-controlling interests (DNCC, JDR and Sitech) of €19 million and including the caprolactam licensing income.
Due to the ownership change of DSM’s caprolactam and acrylonitrile businesses, NewCo automatically becomes an indirect 65% shareholder in Sitech Services, the on-site service provider at the Chemelot Industrial Park in Sittard-Geleen (Netherlands). As a service provider, Sitech generally reinvests the majority of its profit into the Chemelot Industrial Park. DSM will remain a 5% shareholder in Sitech Services via DSM Engineering Plastics. In 2014 Sitech Services generated an EBITDA of €27 million, reported within DSM’s Corporate Activities, of which 65% is included in NewCo’s pro-forma 2014 EBITDA of €106 million mentioned above.
Over the past ten years, DSM has further developed the Chemelot Industrial Park and the Brightlands Chemelot Campus (Research) in Sittard-Geleen (Netherlands) into a world-leading innovation and production location. The close cooperation with the University of Maastricht and the Province of Limburg further enhances this development. Both the Industrial Park and the Campus have a deep-rooted cluster of activities, with over 100 companies and knowledge institutions such as Eindhoven University present, currently employing over 7,000 people, a number which is increasing. DSM is fully committed to its contribution for the further development of the Chemelot Industrial Park and Brightlands Chemelot Campus.
In accordance with the applicable accounting standards, DSM’s caprolactam, acrylonitrile and composite resins businesses will be classified as assets held for sale in Q1 2015 and an initial book loss of approximately €130 million, after tax and non-controlling interests, will be recognized as an exceptional item in Q1 2015. This reflects the estimated value of the assets on a fair value less cost to sell basis, taking into account the specific terms of the transaction. The expected full value of DSM’s remaining 35% stake will be recognized in the future. Post-closing, DSM will present the investment in NewCo as an associate, accounted in accordance with the equity method. Re-stated figures will be made available.
Fibrant confirms that effective today the business activities previously known as DSM Caprolactam have been renamed Fibrant. The intended name change was announced on December 3rd 2015, following the completion of a Joint Venture transaction between CVC Capital Partners (65%) and DSM (35%), to acquire DSM’s global caprolactam activities.
Ascendは、世界最大規模のPA66樹脂の製造会社です。アジポニトリル、ヘキサメチレンジアミン、アジピン酸といったキーとなる化学品中間体を後方統合しており、Vydyne® PA66 のレジンとコンパウンドによる高機能樹脂アプリケーション分野での成長に注力しています。この度の合意により、Ascendは、世界中に販売網を広げることで成長を加速していく計画です。米国フロリダ州ペンサコラにある同社の世界最大規模のPA66製造拠点は、最先端のコンパウンド技術を誇り、近年そのコンパウンド生産量を30kMT増加させています。また、米国サウスカロライナ州グリーンウッドにも製造拠点を保有しています。
SK Capital Partnersは2009年6月、Solutia Inc. からのナイロン事業買収を完了した。新しくAscend Performance Materials を設立した。
2013/5/18 SK Capital Partners の事業
2012年1月、Eastman ChemicalがSolutia Inc. の買収を発表した。2012/2/3 Eastman Chemical、Solutia を買収
DSM、Zhejiang NHU(浙江新和成) と高機能樹脂PPSコンパウンドの製造を手掛ける新会社を設立
DSMは、Zhejiang NHU（浙江新和成股份有限公司）とともに、PPS（ポリフェニレンサルファイド）をベースとする高機能樹脂コンパウンド事業を市場開発事業を手掛ける合弁会社を設立する。同JVが製造するPPSコンパウンド製品は「Xytron PPS」ブランドとして、自動車業界や電子・電機業界を中心に、DSMのマーケティング・セールス部門が中国を含めてグローバルに販売活動を行う。
新会社の名称はDSM NHU Engineering Plastics (Zhejiang) Co. Ltd.で、DSMが60%、NHUが40%保有する。
高機能樹脂の開発を手掛ける子会社Zhejiang NHU Special Materials はPPSを年間5,000トン、特殊ポリアミドのポリフタラミド（PA6T）を2,000トン生産している。
Through the fermentative manufacture of natural marine algae, the new plant produces a special algal oil that contains the key omega-3 fatty acids needed for healthy salmon farming.
The two parent companies of the 50:50 joint venture named Veramaris, have invested a total of $200 million in equal parts for the construction of the plant in Blair, Nebraska.
The initial algal oil produced at the plant can sustainably supply approximately 15% of the annual demand the global salmon-farming industry has for the two omega-3 fatty acids eicosapentaenoic acid エイコサペンタエン酸(EPA) and Docosahexaenoic acid (DHA). The unique process developed by Evonik and DSM enables the manufacture of EPA and DHA for salmon feed for the first time without using any fish oil from wild-caught fish.
“In Veramaris, we have combined the competencies of two strong partners to make an innovative contribution to the healthy nutrition of the world’s growing population, without putting any further burden on our oceans,” says Christian Kullmann, chairman of the Executive Board of Evonik. Feike Sijbesma, CEO/Chairman DSM Managing Board commented: “I am pleased that together with Evonik we have reached a key milestone in turning the tide: through Veramaris, we are able to reduce the aquaculture industry’s reliance on the world’s finite fish oil resources for these vital omega-3 fatty acids. This fits perfectly with our purpose-led performance driven strategy, focused on addressing the world’s biggest challenges while simultaneously creating economic, environmental and societal value for all our stakeholders.”With Veramaris the Animal Nutrition business line has taken a significant step towards becoming an integrated and innovative system supplier of healthy and sustainable animal nutrition. The joint venture not only complements the portfolio of the business line; together with the business line’s activities in the precision livestock farming sector, it forms one of the most important pillars in the further development of Animal Nutrition.
The production of the Veramaris algal oil is based on the natural algae strain Schizochytrium, which DSM has brought to the partnership with Evonik. The joint development of the strain right up to commercial production, and the joint development of the process formed the basis for the new production plant. Evonik constructed the plant on site in Blair next to its existing facility, where it has been running a fermentation process to produce Biolys (source of L-lysine) for many years now. The production complex benefits from many synergies in infrastructure, technology and personnel.
DSM社、Nenter社との ビタミンEに係る ジョイントベンチャー設立を完了
– DSMの基準 に合わせるためのプラントの大幅改修に伴い 生産は停止
栄養、健康、持続可能な暮らしの 分野で意欲的に 活動する グローバル・サイエンス企業Royal DSMは、2019年1月29日に 発表された出資比率75/25によるNenter & Co., Inc.との ジョイントベンチャー(JV) 設立を 完了しました。
またDSMの安全、健康および環境に 関する基準を 順守するための、予定された 改修作業をすぐに開始するため、生産を停止します。 操業停止は、これらの重要な 改修を完了するのに必要な 期間継続します。
JVは、荊州市にあるビタミンE生産施設を取得・運営し、ビタミンEの中間物を 生産する 中国湖北省石首市にあるNenter施設の 株式も少数株主として 保有することになります。
JVでは、DSM向けに 排他的に ビタミンEが生産されることになります。
また、 ビタミンEの高品質で 持続可能 な供給を確保するために施設の改良・改修を行います。
これにより、DSMの安全、健康および環境上の 基準が 順守されることになります。
Nenter & Co., Inc. (能特科技有限公司) is a wholly-owned subsidiary of a listed company named GuanFu joint stock company (冠福股份). Our company was founded in 2006, and the registered capital was RMB 220 million. Currenty, we have 3 production plants, which covers approximately 139 acres in total.
Nenter is a high-tech enterprise producing, developing, and selling medical intermediates, fine chemical and feed additives.
Now we have two products series.
The first one is a series of medical intermediates, and the main products are montelukast sodium intermediates for the treatment of asthma and anti-allergic, and rosuvastatin intermediates for the treatment of hyperlipidemia and high cholesterol.
The second one is a series of Vitamins which developed from Vitamin E and its intermediates.